TNF Inhibitor denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies TNF Inhibitors as Non-Formulary

UHC maintains a tiered formulary and designates specific TNF inhibitors as preferred agents. When your prescriber selects a TNF inhibitor that sits on a non-preferred or non-formulary tier — often because of a rebate arrangement UHC has with a competing product — the claim is denied as non-formulary. This is a coverage-design decision by the insurer, not a clinical judgment about your condition.

## Why This Denial Is Appealable

Non-formulary denials are appealable through a formulary exception request (also called a coverage exception or medical exception). If the preferred TNF inhibitor is medically inappropriate for you — due to a documented intolerance, contraindication, prior failure, or a clinical characteristic that distinguishes the non-preferred agent — you are entitled to an exception. Under ACA §2719 and ERISA §503, you may also pursue internal and then external independent review.

## Federal Appeal Framework

• Formulary exception request: File simultaneously with or before the formal internal appeal; UHC must review and respond within standard utilization-management timelines (or 72 hours on expedited basis).
• Internal appeal: 180 days from denial notice to file.
• External review: Available after final internal denial or if UHC misses its deadline; window is typically four months.
• Expedited track: Available when your health would be seriously jeopardized by standard timeline.

## Documentation to Gather

1. Diagnosis and indication — specialist notes confirming the diagnosis and the specific indication for which the non-preferred TNF inhibitor is prescribed. 2. Preferred-agent failure or contraindication — records showing you tried the formulary-preferred TNF inhibitor and experienced inadequate response, an adverse event, or that it is otherwise clinically unsuitable; or a prescriber attestation explaining why the preferred agent cannot be used. 3. Clinical differentiation — any peer-reviewed basis or clinical characteristic (e.g., route of administration, dosing schedule, disease subtype) that makes the prescribed product the appropriate choice for your specific situation. 4. Prescriber medical-necessity letter — explicitly addressing why the non-preferred agent is medically necessary and why the preferred formulary alternative is not appropriate for this patient. 5. Biosimilar considerations — if the denial involves a reference biologic vs. a biosimilar, confirm with the prescriber whether substitution is clinically appropriate and document the rationale either way.

## Criteria-Mapping Structure

Obtain UHC's current published formulary exception criteria and map each requirement to chart evidence:

| Exception Criterion (from UHC policy) | Supporting Documentation | |---|---| | Formulary alternative tried and failed | Records of prior TNF inhibitor with dates/outcomes | | Formulary alternative contraindicated | Prescriber attestation with clinical basis | | Prescribed agent is medically necessary | Prescriber letter referencing diagnosis + specialty guidelines |

Review the FDA-approved prescribing information for both the prescribed and the preferred agent, and review UHC's current formulary and exception policy, to identify the precise requirements that apply to your plan and benefit year.